16 December 2022 in Science Advances
Epigenetic mediation through bromodomain and extraterminal (BET) proteins have progressively translated protein imbalance into effective cancer treatment. Perturbation of druggable BET proteins through proteolysis-targeting chimeras (PROTACs) has recently contributed to the discovery of effective therapeutics. Unfortunately, precise and microenvironment-activatable BET protein degradation content with promising tumor selectivity and pharmacological suitability remains elusive. Here, we present an enzyme-derived clicking PROTACs (ENCTACs) capable of orthogonally cross-linking two disparate small-molecule warhead ligands that recognize BET bromodomain-containing protein 4 (BRD4) protein and E3 ligase within tumors only upon hypoxia-induced activation of nitroreductase enzyme. This localized formation of heterobifunctional degraders promotes specific down-regulation of BRD4, which subsequently alters expression of epigenetic targets and, therefore, allows precise modulation of hypoxic signaling in live cells, zebrafish, and living mice with solid tumors. Our activation-feedback system demonstrates compelling superiorities and may enable the PROTAC technology with more flexible practicality and druggable potency for precision medicine in the near future.
11 June 2024 in Journal of the American Chemical Society
7 March 2024 in Chemical Science
A rationally designed molecular rotor CCVJ-H shows superior performances than CCVJ-1 in a range of nucleic acid sensing applications, including nucleic acid detection, DNA glycosylase assay, and nucleic acid-small molecule interaction profiling.
1 March 2021 in Tetrahedron
13 September 2023 in Organic Chemistry Frontiers
A bisguanidinium-catalyzed enantioconvergent SN2X reaction is described for the formation of C(sp3)–O bonds from racemic tertiary bromides and hydroxylamides/phenols, enabling efficient synthesis of bioactive compounds such as enantiopure bicalutamide and chiral fibrates.
5 August 2026 in Angewandte Chemie International Edition
RNA protection and controlled release are critical for both fundamental research and therapeutic applications, yet the development of simple, efficient, and reversible post‐synthetic RNA modification strategies remains a significant challenge. Here, we introduce a straightforward approach based on ribose 2′‐hydroxyl acylation with a nitro‐functionalized carbamate, which acts as a redox‐responsive center. This modification selectively inhibits native RNA function while remaining inert to endogenous biogenic reductants and common reducing agents used in biological assays. Upon treatment with low millimolar concentrations of the diboron‐bipyridine reducing pair, RNA function is rapidly restored on a minute timescale. This methodology is broadly applicable across diverse RNA classes and functional contexts, including synthetic RNA oligomers, fluorogenic RNA aptamers, single guide RNAs in CRISPR–Cas9 gene‐editing systems, and mRNAs in living cells for translation control and RNAi‐mediated gene silencing. These results demonstrate the general utility of this approach as a chemically controllable functional switch, providing a versatile toolkit for temporal regulation of RNA activity in both research and biotechnological applications.